Abstract | BACKGROUND: Prophylactic vaccination against infectious diseases may induce a state of long-term protection in the otherwise healthy host. However, the situation is less predictable in immunocompromised patients and may require adjustment of vaccination schedules and/or basic therapy. METHODS: RESULTS: No signs of seroconversion or T cellular memory were observed after the first "full immunization" with Comirnaty. Consequently, long-term-maintenance therapy with Pomalidomide was stopped and two additional shots of Vaxzevria were administered after which the patient seroconverted with Spike(S)- protein specific antibody levels reaching 49 BAU/mL, mild S- peptide pool-specific T cell proliferation, effector cytokine production (IL-2, IL-13), and T cellular activation with increased numbers of CD3+CD4+CD25+ T cells as compared to vaccinated and non-vaccinated control subjects. However, despite suspension of immunosuppression and administration of in total four consecutive heterologous SARS-CoV-2 vaccine shots, the patient did not develop neutralizing RBD-specific antibodies. CONCLUSIONS: Despite immunomonitoring-based adjustment of vaccination and/or therapy schedules vaccination success, with clear correlates of protection, the development of RBD-specific antibodies could not be achieved in the immunocompromised patient with current SARS-CoV-2 vaccines. Thus, our report emphasizes the need for improved active and passive immunization strategies for SARS-CoV-2 infections.
|
Authors | Bernhard Kratzer, Doris Trapin, Pia Gattinger, Teresa Oberhofer, Al Nasar Ahmed Sehgal, Petra Waidhofer-Söllner, Arno Rottal, Ulrike Körmöczi, Katharina Grabmeier-Pfistershammer, Gerhard H Kopetzky, Franz Tischer, Rudolf Valenta, Winfried F Pickl |
Journal | Vaccines
(Vaccines (Basel))
Vol. 10
Issue 3
(Feb 27 2022)
ISSN: 2076-393X [Print] Switzerland |
PMID | 35335006
(Publication Type: Journal Article)
|